Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × darolutamide × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 34 Neoplasm Metastasis 4 Salivary Gland Neoplasms 2 Metastatic Castration-resistant Prostate Cancer 2 Breast Neoplasms 2 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1

Interventions

Surveys and Questionnaires 98 Exercise 88 Blood Specimen Collection 86 Radiotherapy 60 Gemcitabine 53 Bevacizumab 52 Cisplatin 50 Standard of Care 49 Capecitabine 47 Dexamethasone 44 Cyclophosphamide 44 Carboplatin 44 Docetaxel 41 Paclitaxel 40 Interviews as Topic 40 pembrolizumab 39 Oxaliplatin 38 Methods 35 Irinotecan 35 Fluorouracil 35 Magnetic Resonance Spectroscopy 33 Therapeutics 29 Radiosurgery 28 Nivolumab 27 Drug Therapy 26 Educational Status 25 Leucovorin 22 Everolimus 21 Control Groups 21 Cognitive Behavioral Therapy 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡